Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
- PMID: 16679330
- PMCID: PMC1463974
- DOI: 10.1136/bmj.38803.528113.55
Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
Abstract
Objective: To review the evidence for ethnic differences in susceptibility to adverse drug reactions (ADRs) to cardiovascular drugs.
Design: Systematic review and meta-analysis.
Data sources: We searched Medline and Embase to March 2005. Reference lists of identified articles were hand searched for further relevant articles.
Review methods: Studies were eligible for inclusion if they included at least two ethnic groups and one or more ADRs. We excluded case reports and case series.
Results: 564 studies contained some description of ethnicity and an ADR, and 132 of them related to cardiovascular therapies. Twenty four studies provided data for ADRs for at least two ethnic groups and were therefore eligible for inclusion. In pooled analyses the relative risk of angio-oedema from angiotensin converting enzyme (ACE) inhibitors in black compared with non-black patients was 3.0 (95% confidence interval 2.5 to 3.7); the relative risk of cough from ACE inhibitors was 2.7 (1.6 to 4.5) in East Asian compared with white patients; and the relative risk of intracranial haemorrhage with thrombolytic therapy was 1.5 (1.2 to 1.9) in black compared with non-black patients.
Conclusion: Patients from different ethnic groups have different risks for important ADRs to cardiovascular drugs. Ethnic group may therefore be one determinant of harms of a given treatment in the individual patient, either because it acts as a surrogate measure of genetic make up or because cultural factors alter the risk. Data are sparse, and regulators should consider asking for better data before licensing.
Figures
Comment in
-
Ethnicity and adverse drug reactions.BMJ. 2006 May 20;332(7551):1163-4. doi: 10.1136/bmj.332.7551.1163. BMJ. 2006. PMID: 16709964 Free PMC article. No abstract available.
-
Ethnic misclassifications hamper progress in research.BMJ. 2006 Jun 3;332(7553):1335. doi: 10.1136/bmj.332.7553.1335. BMJ. 2006. PMID: 16740577 Free PMC article. No abstract available.
-
Ethnic differences in risks of adverse reactions: Biomedical approach is insufficient to explain ethnic differences.BMJ. 2006 Jun 10;332(7554):1393. doi: 10.1136/bmj.332.7554.1393-a. BMJ. 2006. PMID: 16763266 Free PMC article. No abstract available.
-
Ethnic differences in risks of adverse reactions: is personalised drug treatment better with pharmacokinetic modelling?BMJ. 2006 Jun 10;332(7554):1393. doi: 10.1136/bmj.332.7554.1393. BMJ. 2006. PMID: 16763267 Free PMC article. No abstract available.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Race, ethnicity and medical research.S Afr Med J. 2006 Jul;96(7):606. S Afr Med J. 2006. PMID: 16955954 No abstract available.
-
Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis.Drug Saf. 2008;31(7):597-607. doi: 10.2165/00002018-200831070-00005. Drug Saf. 2008. PMID: 18558793 Review.
-
Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. PMID: 30354042 Free Books & Documents. Review.
-
Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature.JACC Heart Fail. 2019 Mar;7(3):258-266. doi: 10.1016/j.jchf.2019.01.009. JACC Heart Fail. 2019. PMID: 30819382
Cited by
-
Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess.Front Pharmacol. 2024 Oct 24;15:1485067. doi: 10.3389/fphar.2024.1485067. eCollection 2024. Front Pharmacol. 2024. PMID: 39512822 Free PMC article.
-
Prevalence, Characteristics and Factors Associated with Adverse Drug Reactions Among Hospitalized Patients.Hosp Pharm. 2024 Aug;59(4):489-497. doi: 10.1177/00185787241234217. Epub 2024 Feb 22. Hosp Pharm. 2024. PMID: 38919759
-
Delivering biochemicals with precision using bioelectronic devices enhanced with feedback control.PLoS One. 2024 May 14;19(5):e0298286. doi: 10.1371/journal.pone.0298286. eCollection 2024. PLoS One. 2024. PMID: 38743674 Free PMC article.
-
Relationship between antihypertensive drug use and number of people with high blood pressure in FY 2018: a descriptive epidemiological study based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan open data.J Pharm Health Care Sci. 2023 Dec 9;9(1):47. doi: 10.1186/s40780-023-00317-7. J Pharm Health Care Sci. 2023. PMID: 38066634 Free PMC article.
-
Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension.J Renin Angiotensin Aldosterone Syst. 2023 Jun 21;2023:7890188. doi: 10.1155/2023/7890188. eCollection 2023. J Renin Angiotensin Aldosterone Syst. 2023. PMID: 37389408 Free PMC article. Review.
References
-
- Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997;277: 307-11. - PubMed
-
- Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274: 29-34. - PubMed
-
- Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286: 2270-9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous